Oxford BioMedica
Lucinda (Lucy) Crabtree, PhD, serves as the Chief Financial Officer at Oxford Biomedica. Previously, Lucinda held the position of Chief Financial Officer and Member of the Board of Management at MorphoSys AG following its acquisition by Novartis. Lucinda also served as Vice President and Head of Investor Relations at Autolus Ltd. Earlier in Lucinda's career, a role as Senior Investment Analyst at Woodford Investment Management was undertaken.
This person is not in any teams
This person is not in any offices
Oxford BioMedica
2 followers
Oxford Biomedica (LSE: OXB) is a leading, fully integrated, cell and gene therapy group.